1. Scrip
  2. >>Business
  3. >>Earnings

As Vaccine Revenues Flow In, BioNTech Makes Rapid Oncology Push

German Biotech Initiates Multiple IO Programs

 
• By Alaric DeArment

The company also is adding new capabilities, including a cell therapy platform, and it is investing in AI and machine learning, like fellow mRNA player and COVID-19 vaccine maker Moderna.

shutterstock-264802244
BioNTech is doing a major push into immuno-oncology • Source: Shutterstock

BioNTech SE’s claim to fame may be the COVID-19 vaccine it developed with partner Pfizer Inc., but looking beyond the pandemic, the German biotech especially wants to make its presence known in the immuno-oncology space as it ramps up development of several product candidates and platforms in various cancers, including under partnerships with makers of checkpoint inhibitors. To that end, the company has made some significant investments.

Mainz, Germany-based BioNTech announced its second quarter earnings on 9 August. The company reported revenues of €5.3bn ($6.22bn), versus €41.7m ($48.9m) in second quarter 2020. That included commercial revenues of €5.28bn ($6

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

More from Business

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.